Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BCAX vs RAPP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RAPP Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 4–2 Matrix Metrics)

RAPP Overall Winner 6-Pillar Tally: BCAX 2 – 2 RAPP (2 Tie) Matrix Metrics: BCAX 2 – 4 RAPP

As of Nov 16, 2026, Rapport Therapeutics, Inc. (RAPP) is the stronger overall head-to-head candidate over Bicara Therapeutics Inc. (BCAX) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale). BCAX carries a Unified Composite Score of 52.1/100 (HOLD) at $9.75 (N/M Forward P/E, 0.0% operating margin), whereas RAPP carries 51.4/100 (HOLD) at $24.82 (N/M Forward P/E, -838.1% operating margin).

  • Composite vs. Pillar Nuance: While BCAX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. RAPP 51.4/100 HOLD), RAPP captures the overall institutional head-to-head verdict (4–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (-838.1% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: BCAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile RAPP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BCAX vs RAPP
BCAX NASDAQ
Bicara Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$9.75
-2.69% 1D
Market Cap $671.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.42β · 184% Vol
Unified Composite Score
52.1 / 100 HOLD
Tech 58.0 Fund 66.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.1%), weak momentum, RSI 33
RSI-14: 32.7 · SMA20: $11.85 · SMA50: $16.57
RAPP NASDAQ Head-to-Head Winner
Rapport Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$24.82
-5.09% 1D
Market Cap $1.5B
TTM Revenue $20M
Forward P/E N/M
Beta / 30D Vol 1.31β · 108% Vol
Unified Composite Score
51.4 / 100 HOLD
Tech 62.0 Fund 63.0 Flow 68.0 Mom 58.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.6%), weak momentum, RSI 42
RSI-14: 42.4 · SMA20: $25.63 · SMA50: $31.52

6-Pillar Scorecard Institutional Category Breakdown (BCAX 2 – 2 RAPP)

Columns: Metric · BCAX · RAPP
1. Valuation Multiples RAPP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 73.4x
2. Growth & Scale RAPP
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $20M
Market Cap $671.2M $1.5B
3. Profitability & Quality BCAX
Gross Margin N/A N/A
Operating Margin 0.0% -838.1%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -54.2% -33.3%
4. Balance Sheet & Cash Flow BCAX
Cash Generation (TTM) -$163M -$121M
Cash Flow Margin N/A N/A
Net Cash / Leverage $81M Net Cash $65M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 102.7% (23rd %ile) 93.8% (6th %ile)
Put/Call OI Skew N/A 0.91x (Balanced)
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BCAX (2) vs RAPP (4)
Institutional Metric BCAX RAPP Criterion Row Edge
Market Capitalization
Scale
$671.2M $1.5B Larger Scale RAPP
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% -838.1% Higher Margin BCAX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-54.2% -33.3% Higher ROE RAPP
52-Week Range Position
Momentum
8% ($8–$31) 9% ($22–$53) Stronger Trend RAPP
Beta / 30D Volatility
Risk Regime
1.42β · 184% Vol 1.31β · 108% Vol Lower Realized Risk RAPP
Unified Institutional Score
Composite Signal
52.1 / 100 (HOLD) 51.4 / 100 (HOLD) Higher Composite BCAX
Trailing 12M Revenue (USD)
Operating Scale
N/A $20M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 73.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$163M ($81M Net Cash) -$121M ($65M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RAPP +31.93 pp
BCAX: -41.9% · RAPP: -9.97%
3M Horizon RAPP +11.51 pp
BCAX: -60.87% · RAPP: -49.36%
6M Horizon RAPP +20.01 pp
BCAX: -49.46% · RAPP: -29.45%
1Y Horizon RAPP +32.24 pp
BCAX: -31.63% · RAPP: +0.61%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCAX vs RAPP. Trailing 12-month operating profitability (BCAX 0.0% vs RAPP -838.1%) and valuation multiples (BCAX N/M vs RAPP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BCAX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-54.2% · N/M
RAPP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$20M
Gross MarginN/A
Op. Margin-838.1%
ROE / Fwd P/E-33.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BCAX BREAKDOWN
93d in phase · OBV ACCUMULATION
Current IV 102.7%
IV Percentile 23rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact BCAX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RAPP BREAKDOWN
133d in phase · OBV NEUTRAL
Current IV 93.8%
IV Percentile 6th %ile
Put/Call OI Skew 0.91x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact RAPP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BCAX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $671.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RAPP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and -838.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BCAX vs RAPP Key Questions & Quantitative Answers

As of Nov 16, 2026, Rapport Therapeutics, Inc. (RAPP) is the stronger overall head-to-head candidate over Bicara Therapeutics Inc. (BCAX) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale). BCAX carries a Unified Composite Score of 52.1/100 (HOLD) at $9.75 (N/M Forward P/E, 0.0% operating margin), whereas RAPP carries 51.4/100 (HOLD) at $24.82 (N/M Forward P/E, -838.1% operating margin). Composite vs. Pillar Nuance: While BCAX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. RAPP 51.4/100 HOLD), RAPP captures the overall institutional head-to-head verdict (4–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (-838.1% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: BCAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile RAPP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RAPP leads the Growth & Scale pillar: BCAX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with RAPP at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $20M TTM revenue (N/A gross margin, -838.1% operating margin). On trailing 12-month operating scale, BCAX generates N/A in USD-normalized revenue versus $20M for RAPP. In operating R&D and SG&A reinvestment, BCAX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RAPP.

RAPP screens cheaper on headline valuation multiples. BCAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas RAPP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 73.4x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BCAX (-54.2% ROE) versus RAPP (-33.3% ROE) capital efficiency.

In options market volatility and institutional positioning, BCAX carries 102.7% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.42β · 184% Vol realized risk). By comparison, RAPP carries 93.8% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.91x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.31β · 108% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.